Lentiviral vector delivery of short hairpin RNA to NG2 and neurotrophin-3 promotes locomotor recovery in injured rat spinal cord
Date
2012-01-08Author
Donnelly, Eleanor M.
Madigan, Nicolas N.
Rooney, Gemma E.
Knight, Andrew
Chen, Bingkun
Ball, Bret
Kinnavane, Lisa
Garcia, Yolanda
Dockery, Peter
Fraher, John
Strappe, Padraig M.
Windebank, Anthony J.
O'Brien, Timothy
McMahon, Siobhan S.
Metadata
Show full item recordUsage
This item's downloads: 261 (view details)
Cited 17 times in Scopus (view citations)
Recommended Citation
Donnelly, Eleanor M., Madigan, Nicolas N., Rooney, Gemma E., Knight, Andrew, Chen, Bingkun, Ball, Bret, Kinnavane, Lisa, Garcia, Yolanda, Dockery, Peter, Fraher, John, Strappe, Padraig M., Windebank, Anthony J., O'Brien, Timothy, McMahon, Siobhan S. (2012). Lentiviral vector delivery of short hairpin RNA to NG2 and neurotrophin-3 promotes locomotor recovery in injured rat spinal cord. Cytotherapy, 14(10), 1235-1244. doi: https://doi.org/10.3109/14653249.2012.714865
Published Version
Abstract
Background aims. In this study we investigated the effect of neurotrophin-3 (NT-3) and knockdown of NG2, one of the main inhibitory chondroitin sulfate proteoglycans (CSPG), in the glial scar following spinal cord injury (SCI). Methods. Short hairpin (sh) RNA were designed to target NG2 and were cloned into a lentiviral vector (LV). A LV was also constructed containing NT-3. LV expressing NT-3, shRNA to NG2 or combinations of both vectors were injected directly into contused rat spinal cords 1 week post-injury. Six weeks post-injection of LV, spinal cords were examined by histology for changes in scar size and by immunohistochemistry for changes in expression of CSPG, NT-3, astrocytes, neurons and microglia/macrophages. Motor function was assessed using the Basso, Beattie and Bresnahan (BBB) locomotor scale. Results. Animals that received the combination treatment of LV shNG2 and LV NT-3 showed reduced scar size. These animals also showed an increase in levels of neurons and NG2, a decrease in levels of astrocytes and a significant functional recovery as assessed using the BBB locomotor scale at 2 weeks post-treatment. Conclusions. The improvement in locomotor recovery and decrease in scar size shows the potential of this gene therapy approach as a therapeutic treatment for SCI.